GlassScriptPhysician profile
Hope Engelbrecht
NPI 1407388531
$351.79
in general payments reported to CMS, 2019-2025
11 companies · $232 in 2025
The $232 reported for 2025 was more than what 82% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
See the full distribution for Hospice and Palliative Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $120 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $82.66 | 2024-2025 | Reblozyl, Opdivo, Opdualag |
| Daiichi Sankyo INC. | $50.12 | 2024-2025 | Vanflyta, Injectafer |
| Regeneron Healthcare Solutions, INC. | $40.93 | 2025 | Libtayo, Lynozyfic |
| Abbvie INC. | $32.27 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $26.96 | 2024 | Enhertu |
| Kite Pharma, INC. | $25.71 | 2025 | Yescarta |
| Janssen Biotech, INC. | $22.88 | 2025 | Rybrevant |
| Sobi, INC | $20.67 | 2025 | |
| Eisai INC. | $17.35 | 2024 | |
| Genentech USA, INC. | $16.72 | 2025 | Tecentriq |
| Tersera Therapeutics LLC | $15.52 | 2024 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Engelbrecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.